




Randomised controlled trials (RCTs) have demonstrated comparable early 4 
oncological outcomes after hypofractionated (H-RT) and conventionally fractionated 5 
radiation therapy (C-RT) in the radical treatment of prostate cancer (PCa). The effect 6 
of hypofractionation on treatment-related (gastrointestinal) GI and (genitourinary) GU 7 
toxicity remains uncertain, especially in older men and those with locally advanced 8 
PCa. 9 
 10 
Materials and Methods 11 
Population-based study of all patients treated with radical C-RT (n=9,106) and H-RT 12 
(n= 3,027) in all radiotherapy centres in the English National Health Service between 13 
2014 and 2016. We identified severe GI and GU toxicity using a validated coding-14 
framework and compared C-RT and H-RT using a competing-risks proportional 15 
hazards regression analysis. 16 
 17 
Results 18 
The median age in our cohort was 72 years old and the majority of patients had 19 
locally advanced disease (65%). There was no difference in GI toxicity (C-RT: 5.0 20 
events/100 person-years; H-RT: 5.2 events/100 person-years; adjusted sHR: 1.00, 21 
95%CI: 0.89-1.13; p=0.95) or GU toxicity (C-RT: 2.3 events/100 person-years; H-RT: 22 
2.3 events/100 person-years; adjusted sHR: 0.92, 95%CI: 0.77 -1.10; p=0.35) 23 




This national cohort study has demonstrated the use of H-RT in the radical treatment 27 
of PCa does not increase rates of severe GI or GU toxicity. Our findings also support 28 





























External beam radiotherapy (RT) is a well-established treatment for localised and 57 
locally advanced prostate cancer (PCa). A conventionally fractionated regimen (C-58 
RT, 1.8 – 2 Gy per fraction) delivered over 7-8 weeks has been widely used as 59 
standard of care for primary treatment of PCa (1). However, the use of 60 
hypofractionated regimens (H-RT), which deliver >2Gy over 4 weeks, may offer a 61 
therapeutic and economic advantage by delivering an equivalent biologically effective 62 
dose in a shorter time (2). 63 
 64 
Four recent non-inferiority randomised controlled trials (RCTs) have demonstrated 65 
the comparable efficacy of C-RT and H-RT without significant differences in 5-year 66 
biochemical or clinical failure-free survival in localised PCa (3-7). However, these 67 
RCTs and meta-analyses (2, 8) have reported conflicting data on the effect of 68 
hypofractionation on patient/physician-reported acute and late gastrointestinal (GI) 69 
and genitourinary (GU) toxicity.  70 
 71 
“Real-world” data provide an opportunity to understand the true comparative toxicity 72 
between C-RT and H-RT. We carried out a contemporary national cohort study, 73 
including more than 12,000 patients from all English National Health Service (NHS) 74 
RT centres, who were diagnosed with PCa between 2014 and 2016 and received 75 
either C-RT or H-RT. We used a validated coding system that was specifically 76 
developed to identify severe GI and GU toxicity. The identified toxicity is comparable 77 
to grade 3 toxicity as measured by the National Cancer Institute Common Toxicity 78 
Criteria (CTCAE) for Adverse Events scoring system (version 4.0). In addition, this 79 
coding system also included patients with confirmed radiation proctitis (Grade 2 – 80 





Data sources and patient population 85 
 86 
English cancer registry data (11) linked with prospective data from the National 87 
Prostate Cancer Audit (NPCA) and the National Radiotherapy Dataset (RTDS) (12) 88 
were used to identify men with a diagnosis of PCa (ICD-10 “C61”) who received 89 
intensity-modulated radical RT between April 1, 2014 and March 31, 2016. The use 90 
of intensity-modulated radiotherapy (IMRT) was captured using the OPCS-4 code 91 
“X671” within RTDS.  These men were then linked to the Hospital Episode Statistics 92 
(HES) database, an administrative database of all care episodes in the English NHS 93 
(13).   94 
 95 
Patient and disease characteristics 96 
 97 
Data items in HES records were used to determine age, comorbidities and 98 
socioeconomic deprivation status. The Royal College of Surgeons (RCS) Charlson 99 
score was used to identify any comorbidities a year prior to their PCa diagnosis (14).  100 
Socioeconomic deprivation status was determined for patients from the English 2012 101 
Index of Multiple Deprivation (IMD) based on their area of residence and divided 102 
according quintiles of national distribution (15). Patient demographics, the use of 103 
androgen deprivation therapy and tumour characteristics including TNM-stage and 104 
Gleason score were extracted from the linked NPCA-cancer registry data to 105 
determine a modified D’Amico prostate cancer risk-classification using an algorithm 106 
developed by the NPCA (16). RTDS provided information on the RT treatment region 107 
(prostate only/prostate and pelvic lymph nodes) and the total dose/fractions received.  108 
 109 
Inclusion and exclusion criteria  110 
 
 111 
The records of 12,133 men with non-metastatic prostate cancer who received radical 112 
RT at all RT centres in the English NHS (n=52) were studied. Patients were only 113 
included if they received a known conventional or hypofractionated regimen, as 114 
variation exists in the regimens delivered across RT centres in the United Kingdom 115 
(UK). With reference to the UK RT dose fractionation guidance and regimens used in 116 
RCTs (1, 3-7) we defined C-RT as patients receiving 72 to 79 Gy in 35-40 fractions; 117 
72 Gy/32 fractions; 69 Gy/37 fractions and 70Gy/35 fractions. The median dose 118 
delivered in C-RT group was 74 Gy/37 fractions. H-RT was defined as patients 119 
receiving 50-60 Gy in 16-20 fractions (median 60 Gy/20 fractions). 120 
 121 
Patient were excluded if they had an associated diagnosis of bladder cancer (ICD-10 122 
“C67”) (n= 290) or if there was any missing clinical data (n= 291). The final cohort 123 
included 12,133 men (Figure 1).  124 
 125 
Coding framework 126 
 127 
We used previously validated performance indicators to capture severe GI or GU 128 
toxicity following radical RT (10). The coding framework was based on procedures 129 
which are coded using the UK Office for Population Census and Surveys 130 
classification, 4th revision (17), and the diagnostic codes determined using the 131 
International classification of Diseases, 10th revision (ICD-10) (18). Men were 132 
classified as having experienced a complication if both a procedure and 133 
corresponding diagnosis code were present in a patient record following the start of 134 
RT. This approach confined our analyses to severe complications (i.e. requiring 135 
hospital admission or procedural intervention)(9).  136 
 137 
 
The baseline GI and GU function of the included patients was estimated based on 138 
the presence of a GI or GU procedure code in the HES record up to one year before 139 
the start of RT. 140 
 141 
Primary outcome measure 142 
 143 
Time from the date of the first RT treatment to the first GI or GU complication 144 
requiring an intervention were the study primary outcomes. Patients were considered 145 
as not having experienced GI or GU toxicity if the relevant procedure and diagnosis 146 





The 3-year cumulative incidence of both GI and GU complications were calculated 152 
using a competing risks method where death was the competing event (19). We also 153 
calculated incidence rates using total events per 100 person-years, where person-154 
years was calculated as the sum of the time from radiotherapy until occurrence of an 155 
event (GI or GU complication), death or the end of follow-up, whichever occurred 156 
first.  157 
 158 
Statistical analysis 159 
 160 
A competing risks regression analysis, according to Fine and Gray (1999) via 161 
maximum likelihood, was used to estimate subdistribution hazard ratios (sHR) 162 
comparing the risk of GI or GU complications between C-RT and H-RT groups. 163 
When men reached the end of follow-up this was treated as a censoring event. The 164 
regression analysis was adjusted for patient, tumour and treatment characteristics. 165 
 
 166 
Results are reported as sHRs with 95% confidence intervals (95%CI). A p-value 167 
smaller than 0.05 was considered statistically significant. P-values were based on the 168 





























Patient population 197 
 198 
Table 1 presents the characteristics of the study population. Out of the 12,133 men 199 
included, 9,106 (75.1%) received C-RT and 3,027 (24.9%) received H-RT. The 200 
median age (interquartile range) of all included men was 72 (67 - 76) years. The use 201 
of H-RT increased over the study period – 394 out of 1,849 men (21.3%) in 2014 202 
compared to 969 out of 2,439 men (39.7%) in 2016. 203 
 204 
In the H-RT group men were older (8.4% versus 5.4%, >80 years), fewer men had 205 
locally advanced disease (58.0% versus 66.9%), and fewer men received RT to 206 
prostate and pelvic lymph nodes (10.8% versus 15.6%). Baseline GI and GU toxicity 207 
were also similar in both groups. 208 
 209 
Gastrointestinal and genitourinary toxicity 210 
 211 
Patients experienced 5.1 GI events/100 person years of follow-up in the C-RT group 212 
compared to 5.3 in the H-RT group (unadjusted HR: 1.02 (0.91 – 1.15)). With respect 213 
to GU events, patients who received C-RT experienced 2.3 GU events/100 person 214 
years of follow-up compared to 2.3 in the H-RT group (unadjusted HR: 1.00 (0.84 – 215 
1.19)) (Table 2). Median (interquartile range) follow-up was 2.6 (2.3 – 3.0) years for 216 
all men in the study; 2.7 (2.3 – 3.0) years for C-RT group and 2.4 (2.1 – 2.9) years for 217 
H-RT group. 218 
 219 
The cumulative incidence of GI toxicity was higher in the H-RT group up to 220 
approximately 1 year (4.3% compared to 3.2%) however at 3 years they were similar 221 
 
(13.4% in C-RT group, 13.7% H-RT group) (Figure 2). GU toxicity remained similar in 222 
both groups throughout the follow-up period (Figure 3). 223 
 224 
Following adjustment and using a competing-risks approach we found that there was 225 
no statistically significant difference in GI toxicity (sHR: 1.00; 95% CI: 0.89 – 1.13, p= 226 
0.95) or GU toxicity (sHR: 0.92; 95% CI: 0.77 – 1.10, p=0.35) between both groups 227 



























In this national population-based study of more than 12,000 men with PCa we found 254 
no overall difference in severe GI and GU toxicity between patients who received C-255 
RT and H-RT. There was a trend towards increased GI toxicity in the H-RT group up 256 
to 1 year after treatment although this was not seen at the end of follow-up at 3 257 
years.  258 
 259 
Our study also included men who are older and more often have locally advanced 260 
disease compared to existing RCTs. All men in the study received recognised 261 
conventionally fractionated and hypofractionated radical RT regimens which were 262 
delivered using contemporary IMRT, and furthermore toxicity was captured using a 263 
validated outcome measure. 264 
 265 
Comparison with other studies 266 
 267 
There is increasing evidence supporting the use of H-RT for men with PCa. Four 268 
large RCTs demonstrated similar 5-year effectiveness data after H-RT for 269 
biochemical and clinical failure-free survival in localised PCa (3-6, 20). However, 270 
there have been differences with regard to treatment-related toxicity outcomes. The 271 
PROFIT trial randomised 1,206 men with intermediate-risk disease and found 272 
significantly lower late GI toxicity rates (grade ≥2, RTOG score) in the 273 
hypofractionated (60 Gy/20 fractions) arm compared to the conventional arm (78 274 
Gy/39 fractions). These results were in contrast to the RTOG 0415 study which 275 
included 1,092 men all with low-risk disease and reported an increase in both late GI 276 
and GU ≥2 toxicity (NCI CTCAE scoring system) in the hypofractionated group (70 277 
 
Gy/28 fractions) compared to conventional group (73.8Gy/41 fractions). Both of these 278 
studies did not find a difference in acute ≥3 GI and GU toxicity.  279 
 280 
The CHHiP trial included 3,216 men with predominantly intermediate-risk disease 281 
and compared a conventional regimen (74 Gy/37 fractions) with two hypofractionated 282 
schedules (60 Gy/20 fractions and 57 Gy/19 fractions). Similar to our study, CHHiP 283 
reported significantly more acute GI toxicity (≥ grade 2, RTOG score) in both 284 
hypofractionated groups (38%) compared to the conventional group (25%), however 285 
by 18 weeks this difference was no longer present. In our study increased GI toxicity 286 
persisted in the H-RT group up to 1 year. This may be due to our study having a 287 
higher proportion of men with high-risk localised/locally advanced disease (65%) 288 
compared to CHHiP (12%) as well as some men receiving RT to pelvic nodes in our 289 
study which was an exclusion criterion in CHHiP. However, in line with our findings, 290 
CHHiP reported no difference in long-term GI toxicity and also no difference between 291 
groups in terms of acute/long-term GU toxicity.  292 
 293 
The Dutch HYPRO trial included men with predominantly high-risk disease and 294 
demonstrated acute ≥2 GI toxicity (RTOG score) was higher with hypofractionation 295 
(C-RT 31%, H-RT 42%; P 0.0015) although this difference disappeared after 3 296 
months. The incidence of late GI ≥2 toxicity was similar in both groups. The 297 
incidence of acute GU ≥2 toxicity was also similar in both group but in contrast to our 298 
study, the cumulative incidence of late GU ≥2 toxicity was higher in the H-RT arm.   299 
 300 
Most existing retrospective studies have demonstrated similar GI and GU toxicity 301 
with hypofractionation but were predominantly performed at a single institution and 302 
report on a low numbers of patients (21, 22).  303 
 304 
Strengths and limitations 305 
 
 306 
The current study has a number of strengths. First, to our knowledge, this is the 307 
largest comparative study assessing toxicity following C-RT and H-RT and also 308 
exclusively includes patients treated with IMRT. In contrast, some of the major RCTs 309 
have included patients that received 3D-conformal RT (3, 6). 310 
 311 
Second, our findings are reflective of “real-world” practice as we included all men 312 
diagnosed with PCa and treated at any NHS RT centres in the study period. Patients 313 
who underwent RT in the private sector were not included but these men represent 314 
less than 10% of the national case load (23).  315 
 316 
Third, we report on an unselected population with appropriate variation in age and 317 
PCa risk distribution, increasing the generalisability of our results. The large RCTs 318 
(3-7) predominantly reported on intermediate-risk disease with some reporting on 319 
exclusively low-risk (6) and intermediate-risk disease (3). In contrast, our study 320 
included 7,844 men with locally advanced disease, many of whom would have 321 
received higher doses to the seminal vesicles which could increase toxicity rates. 322 
Our population was also older (median age = 72 years) than cohorts used in the 323 
larger RCTs and therefore more reflective of patients encountered in routine clinical 324 
practice. Our findings also confirm the safety of H-RT in older patients and those with 325 
more advanced disease. 326 
 327 
Fourth, through linkage with RTDS, we extracted detailed information regarding RT 328 
doses and patient attendances. As a result we only included men who received 329 
recognised conventional and hypofractionated regimens.  330 
 331 
Finally, the indicators we utilised have been specifically developed and validated to 332 
capture RT-related toxicity severe enough to require admission or an intervention 333 
 
which allowed us to measure GI and GU toxicity at a specific severity level. The 334 
supplementary use of diagnostic codes improved the validity of the indicator and 335 
allowed better identification of RT-related toxicity which we have previously used to 336 
compare different RT delivery techniques (10). Also using observational data to 337 
capture adverse events provides a more accurate reflection of the frequency of 338 
toxicity compared to super-selected RCT populations which often result in under-339 
estimation (24). Of note, RCTs are increasingly advocating linkage to routine health 340 
records to more accurately capture treatment-related adverse events (25). 341 
 342 
There are some limitations to this study. We adjusted the comparison of incidence of 343 
toxicity in the C-RT and H-RT groups for differences in a number of patient, disease 344 
and treatment characteristics. However, we could not control for additional 345 
therapeutic differences including the use of image-guided radiotherapy (IGRT). 346 
Retrospective studies have demonstrated IGRT can reduce late GU and GI toxicity 347 
(26-28). However, it is likely most men received IGRT in this cohort as a snapshot 348 
UK survey showed two-thirds of centres were using IGRT in March 2014, with this 349 
number likely to have increased over time (29). Furthermore, one would not expect 350 
there to be a significant difference in the use of IGRT across the H-RT and C-RT 351 
groups in the IMRT era.  Although we report no difference in toxicity at 3 years, this 352 
may be too early to rule of later toxicity. However, one would expect some 353 
divergence in curves at 3 years if a difference were to exist later. Also, although we 354 
used a validated indicator to capture severe toxicity, we were unable to use our 355 
coding system to identify those who experienced less severe toxicity, which can still 356 
have an impact on quality of life. Finally, we did not have information about baseline 357 
bowel and urinary function of included patients but used and adjusted for the 358 
presence of a prior GI or GU procedure in the year before RT treatment, which acted 359 
as a surrogate for baseline function. 360 
 361 
 
Clinical implications 362 
 363 
The key benefits of hypofractionation are a shorter duration of treatment which 364 
increases patient convenience as well as a reduction in the use of RT resources 365 
which improves cost-effectiveness. However, avoidance of excessive toxicity is 366 
essential for hypofractionated regimens to be adopted into standard practice. 367 
Although large RCTs have demonstrated similar effectiveness with regard to early 368 
cancer control, there has been some uncertainty about treatment-related toxicity. 369 
 370 
Our study, based on a large unselected “real-world” population has shown no 371 
difference in long-term GI and GU toxicity between C-RT and H-RT. Also given we 372 
captured severe toxicity (requiring hospital admission or an intervention which incurs 373 
a high cost) this further strengthens the cost-effectiveness of H-RT. Our findings 374 
support the growing evidence base for the use of H-RT in all men with non-375 
metastatic PCa which has recently been advocated by both UK and international 376 




This national population-based study has demonstrated that the use of H-RT in the 381 
radical management of PCa does not increase rates of severe GI or GU toxicity. Our 382 
findings strengthen recent guidelines supporting the use of H-RT in the management 383 
of non-metastatic PCa, especially in elderly men and those with locally advanced 384 
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 C-RT H-RT All men 
 n % n % n %       p-value 
No. of patients 9,106 75.1 3,027 24.9 12,133 100 
Treatment year      
2014 1,455 16 394 13 1,849 15.2 
2015 6,181 67.9 1,664 55 7,845 64.7 
2016 1,470 16.1 969 32 2,439 20.1      <0.001 
Age (years)      
≤60 3,678 40.4 985 32.5 4,663 38.4 
61-70 2,621 28.8 840 27.8 3,461 28.5 
71-80 2,314 25.4 947 31.3 3,261 26.9 
>80 493 5.4 255 8.4 748 6.2        <0.001 
Comorbidities      
0 6,950 76.3 2,220 73.3 9,170 75.6 
1 1,558 17.1 592 19.6 2,150 17.7 
≥2 598 6.6 215 7.1 813 6.7          0.003 
Socioeconomic deprivation     
1 2,070 22.7 719 23.8 2,789 23 
2 2,206 24.2 626 20.7 2,832 23.3 
3 2,018 22.2 620 20.5 2,638 21.7 
4 1,532 16.8 573 18.9 2,105 17.3 
5 1,280 14.1 489 16.2 1,769 14.6      <0.001 
Androgen deprivation 
No 1,669 18.3 758 25 2,427 20 
Yes 7,437 81.7 2,269 75 9,706 80         <0.001 
Urinary procedure 1 year prior to RT 
No 7,283 80 2,299 75.9 9,582 79 
Yes 1,823 20 728 24.1 2,551 21         <0.001 
Bowel procedure 1 year prior to RT 
No 8,638 94.9 2,881 95.2 11,519 94.9 
Yes 468 5.1 146 4.8 614 5.1          0.492 
Cancer risk profile       
Locally 
advanced/High-risk 6,089 66.9 1,755 58 7,844 64.7 
Intermediate risk 2,923 32.1 1,193 39.4 4,116 33.9 
Low risk 94 1 79 2.6 173 1.4        <0.001 
RT treatment region     
Prostate only 7,681 84.4 2,701 89.2 10,382 85.6 
Prostate	&	Pelvic	





Table 2: Adjusted outcomes for GU and GI toxicity following radical radiotherapy: 535 
















































0.95	 2.3	 6.5	 0.92	
(0.77-
1.10)	
0.35	
